MedTrace Logo

Epoetin Alfa for HIV-Associated Neuropathy Trial

NCT00528593 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-08-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of epoetin alfa on HIV-associated neuropathy by measuring changes in nerve fiber density and pain ratings.

Conditions

Interventions

DRUG

epoetin alfa

Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.

Sponsors & Collaborators

  • Ortho Biotech Clinical Affairs, L.L.C.

    collaborator INDUSTRY

  • PPD Development, LP

    collaborator INDUSTRY

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Justin McArthur, MBBS, MPH · Professor of Neurology, Johns Hopkins University

  • David B. Clifford, MD · Professor of Neurology, Washington University

  • David Simpson, MD · Professor of Neurology, Mt. Sinai Medical Center

  • Bruce Cohen, MD · Professor of Neurology, Northwestern University

  • Pablo Tebas, MD · Associate Professor of Medicine, University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-10-31
Completion
2009-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00528593 on ClinicalTrials.gov